Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin dosing regimens in acute kidney injury
IRCT20130917014693N16Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2023
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of vancomycin in acute kidney failure (AKF) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Percentage of patients who reach therapeutic level and AUC/MIC >= 400. Started Mar 2023; status: completed.
02
Drugs
vancomycin
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on IRCT20130917014693N16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130917014693N16.